Coya Therapeutics develops biologic treatments that aim to restore regulatory T cell function for patients with serious diseases. COYA reports earnings on Wed, Nov 11, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 15 | BTIG | Reiterated | Buy | |
| Aug 24 | Roth Capital | Reiterated | Buy | |
| Aug 12 | Chardan Capital | Maintained | Buy | |
| Jun 5 | Roth Capital | Initiated | Buy |
Seasonality
How COYA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.
Whale Options Flow
90DNo whale options trades in COYA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether COYA is in one of them and how their past COYA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered COYA in an article yet. Here's the latest on the wider market.
About Coya Therapeutics
Coya Therapeutics is a biotechnology company based in Houston, Texas. It is developing treatments that aim to restore the function of regulatory T cells, immune cells that help keep inflammation in check. Its lead candidate, COYA 302, is in clinical testing for amyotrophic lateral sclerosis and is also planned for frontotemporal dementia. The company's therapies are intended for patients with neurodegenerative, autoimmune and metabolic diseases.
- Headquarters
- Houston, TX